$NOVO 

Novo Nordisk which announced results from the phase 1b/2a clinical trial with amycretin in the treatment of overweight and obesity. At 36 weeks, a 22 percent weight loss was noted with 20 milligrams, which compares to a weight gain for those treated with placebo.

#novo
#NOVO #novo